We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

1 hedge funds and large institutions have $6K invested in ELITE PHARMACEUTICAL in 2018 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $5.52K → $6K (+$480)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
JAFL
1
Jay A. Fishman Ltd
Michigan
$6K – – –

ELI Hedge Fund Activity: Q1 2018 in Review

1 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2018, worth a combined $6K — up 8.7% from $5.52K a quarter earlier.

Fund positioning in ELI was balanced in Q1 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $6K of ELITE PHARMACEUTICAL stock for Q1 2018, up 8.7% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q1 2018 and 0 closed out.

Based on aggregated 13F filings for Q1 2018.